Company intelligence / Profile preview
Technovalia
Melbourne, Australiatechnovalia.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
COVIGEN, a plasmid-DNA COVID‑19 vaccine developed by Technovalia and BioNet, was the first of its kind tested in Australia. Interim phase 1 results showed it was well tolerated with no safety concerns. The company also participates in booster studies using this candidate. Other programs include a chikungunya prophylactic vaccine at preclinical stage and involvement in clinical evaluation of recombinant acellular pertussis vaccines through partnerships.
- Therapeutic areas
- Infectious Diseases
- Modalities
- DNA vaccinemRNA-based drugsRecombinant proteinProphylactic vaccine
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
BioNet AsiaSypharmaPharmaJet®The Telethon Kids Institute WAMonash UniversityGenetis (JV)
Beyond the preview
Go deeper on Technovalia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Technovalia.